Description: HLB Therapeutics Co.,Ltd. develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmologic diseases, such as dry eye syndrome and neurotrophic keratopathy; GBT-101 for treating epidermolysis bullosa dermal disease; and OKN-007 for the treatment of glioblastoma brain cancer. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components such as motors, pumps, and trances. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB Therapeutics Co.,Ltd. in December 2021. HLB Therapeutics Co.,Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.
Home Page: www.gtreebnt.com
Parkview Tower
Seongnam-si,
South Korea
Phone:
82 3 1786 7800
Officers
| Name | Title |
|---|---|
| Yong-Kook Kang | Chief Exec. Officer |
| Mr. Doug Jang | Founder |
| Byung-Gi Kim | Head of Management Support Division and Managing Director |
| Sang-Ki Lee | Head of S/W Devel. Division and Sr. Managing Director |
| Man-Soo Kim | Head of Research Center and Assistant Managing Director |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Information Technology |
|---|---|
| GIC Group: | Technology Hardware & Equipment |
| GIC Industry: | Electronic Equipment, Instruments & Components |
| GIC Sub-Industry: | Electronic Components |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 7.1739 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 86 |